|
|
|
|
 |
|
|
       |
|
|
|
 Vasogen's products in development target destructive chronic inflammation. Vasogen's lead product, the Celacade™ technology, has received European regulatory approval under the CE Mark for the treatment of chronic heart failure.  |
|
|
|
| © Vasogen Inc. 2008. Legal Notice | Privacy Policy |  Contact Us  Search  Site Map  Printable Page |
Leadership
